WO2003074671A3 - Mbcats as modifiers of the beta-catenin pathway and methods of use - Google Patents

Mbcats as modifiers of the beta-catenin pathway and methods of use Download PDF

Info

Publication number
WO2003074671A3
WO2003074671A3 PCT/US2003/006359 US0306359W WO03074671A3 WO 2003074671 A3 WO2003074671 A3 WO 2003074671A3 US 0306359 W US0306359 W US 0306359W WO 03074671 A3 WO03074671 A3 WO 03074671A3
Authority
WO
WIPO (PCT)
Prior art keywords
beta
methods
mbcats
modifiers
catenin pathway
Prior art date
Application number
PCT/US2003/006359
Other languages
French (fr)
Other versions
WO2003074671A2 (en
Inventor
Michael A Costa
Steven Brian Gendreau
Emery G Dora Iii
Monique Nicoll
Timothy S Heuer
Original Assignee
Exelixis Inc
Michael A Costa
Steven Brian Gendreau
Emery G Dora Iii
Monique Nicoll
Timothy S Heuer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Michael A Costa, Steven Brian Gendreau, Emery G Dora Iii, Monique Nicoll, Timothy S Heuer filed Critical Exelixis Inc
Priority to AU2003213662A priority Critical patent/AU2003213662A1/en
Publication of WO2003074671A2 publication Critical patent/WO2003074671A2/en
Publication of WO2003074671A3 publication Critical patent/WO2003074671A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

Human MBCAT genes are identified as modulators of the beta-catenin pathway, and thus are therapeutic targets for disorders associated with defective beta-catenin function. Methods for identifying modulators of beta-catenin, comprising screening for agents that modulate the activity of MBCAT are provided.
PCT/US2003/006359 2002-03-01 2003-02-28 Mbcats as modifiers of the beta-catenin pathway and methods of use WO2003074671A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003213662A AU2003213662A1 (en) 2002-03-01 2003-02-28 Mbcats as modifiers of the beta-catenin pathway and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36124302P 2002-03-01 2002-03-01
US60/361,243 2002-03-01

Publications (2)

Publication Number Publication Date
WO2003074671A2 WO2003074671A2 (en) 2003-09-12
WO2003074671A3 true WO2003074671A3 (en) 2004-05-06

Family

ID=27789097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/006359 WO2003074671A2 (en) 2002-03-01 2003-02-28 Mbcats as modifiers of the beta-catenin pathway and methods of use

Country Status (2)

Country Link
AU (1) AU2003213662A1 (en)
WO (1) WO2003074671A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057270A2 (en) * 1998-05-01 1999-11-11 Incyte Pharmaceuticals, Inc. Human receptor molecules
US6001622A (en) * 1995-12-21 1999-12-14 Sunnybrook Health Science Centre Integrin-linked kinase and its use
WO2000000503A1 (en) * 1998-06-26 2000-01-06 The Regents Of The University Of California Human az-1 gene, variants thereof and expressed gene products
WO2000053632A1 (en) * 1999-03-09 2000-09-14 Mcgill University Compounds and methods for stimulating gene expression and cellular differentiation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001622A (en) * 1995-12-21 1999-12-14 Sunnybrook Health Science Centre Integrin-linked kinase and its use
WO1999057270A2 (en) * 1998-05-01 1999-11-11 Incyte Pharmaceuticals, Inc. Human receptor molecules
WO2000000503A1 (en) * 1998-06-26 2000-01-06 The Regents Of The University Of California Human az-1 gene, variants thereof and expressed gene products
WO2000053632A1 (en) * 1999-03-09 2000-09-14 Mcgill University Compounds and methods for stimulating gene expression and cellular differentiation

Also Published As

Publication number Publication date
WO2003074671A2 (en) 2003-09-12
AU2003213662A1 (en) 2003-09-16
AU2003213662A8 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
WO2003083047A3 (en) MP53s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2002099138A3 (en) HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE
WO2002098356A3 (en) Ppp2cs as modifiers of the p53 pathway and methods of use
WO2005016287A3 (en) Prkwnks as modifiers of the rac pathway and methods of use
WO2003051905A3 (en) Taojiks as modifiers of the beta-catenin pathway and methods of use
WO2002099043A3 (en) P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2004013309A3 (en) PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
WO2004024882A3 (en) FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
EP1438432A4 (en) Lrrcaps as modifiers of the p53 pathway and methods of use
WO2005017121A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004014301A3 (en) PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE
WO2004061123A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2003074725A3 (en) MBCATs AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE
WO2004015071A3 (en) CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004048538A3 (en) Csnks as modifiers of the rac pathway and methods of use
WO2004083389A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2005017123A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2004065542A3 (en) MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2003052068A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004048541A3 (en) Cct6s as modifiers of the rb pathway and methods of use
WO2004047761A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2003074671A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2003074673A3 (en) Lgals as modifiers of the chk pathway and methods of use
WO2003074677A3 (en) MCHKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE
WO2004083447A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP